These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30739116)

  • 61. A novel mutation of α-galactosidase A gene causes Fabry disease mimicking primary erythromelalgia in a Chinese family.
    Ge W; Wei B; Zhu H; Miao Z; Zhang W; Leng C; Li J; Zhang D; Sun M; Xu X
    Int J Neurosci; 2017 May; 127(5):448-453. PubMed ID: 27211852
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The frequency of Fabry disease with the E66Q variant in the α-galactosidase A gene in Japanese dialysis patients: a case report and a literature review.
    Kikumoto Y; Sugiyama H; Morinaga H; Inoue T; Takiue K; Kitagawa M; Saito D; Takatori Y; Kinomura M; Kitamura S; Akagi S; Sada K; Nakao K; Maeshima Y; Kitayama H; Makino H
    Clin Nephrol; 2012 Sep; 78(3):224-9. PubMed ID: 22874111
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy.
    Monserrat L; Gimeno-Blanes JR; Marín F; Hermida-Prieto M; García-Honrubia A; Pérez I; Fernández X; de Nicolas R; de la Morena G; Payá E; Yagüe J; Egido J
    J Am Coll Cardiol; 2007 Dec; 50(25):2399-403. PubMed ID: 18154965
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fabry Disease on Peritoneal Dialysis with Cardiac Involvement.
    Koga-Kobori S; Sawa N; Kido R; Sekine A; Mizuno H; Yamanouchi M; Hayami N; Suwabe T; Hoshino J; Kinowaki K; Ohashi K; Fujii T; Ubara Y
    Intern Med; 2021 May; 60(10):1561-1565. PubMed ID: 33361676
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease.
    Niemann M; Rolfs A; Störk S; Bijnens B; Breunig F; Beer M; Ertl G; Wanner C; Weidemann F
    Circ Cardiovasc Genet; 2014 Feb; 7(1):8-16. PubMed ID: 24395922
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Case-finding in Fabry disease: experience from the North of England.
    Brennan P; Parkes O
    J Inherit Metab Dis; 2014 Jan; 37(1):103-7. PubMed ID: 23828401
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
    Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
    Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test.
    Andrade J; Waters PJ; Singh RS; Levin A; Toh BC; Vallance HD; Sirrs S
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):139-45. PubMed ID: 18003767
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study--screening genetic conditions in Portuguese young stroke patients.
    Baptista MV; Ferreira S; Pinho-E-Melo T; Carvalho M; Cruz VT; Carmona C; Silva FA; Tuna A; Rodrigues M; Ferreira C; Pinto AA; Leitão A; Gabriel JP; Calado S; Oliveira JP; Ferro JM;
    Stroke; 2010 Mar; 41(3):431-6. PubMed ID: 20110537
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Benefits of Family Screening in Rare Diseases: Genetic Testing Reveals 165 New Cases of Fabry Disease among At-Risk Family Members of 83 Index Patients.
    Moiseev S; Tao E; Moiseev A; Bulanov N; Filatova E; Fomin V; Germain DP
    Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140787
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fabry Disease in Families With Hypertrophic Cardiomyopathy: Clinical Manifestations in the Classic and Later-Onset Phenotypes.
    Adalsteinsdottir B; Palsson R; Desnick RJ; Gardarsdottir M; Teekakirikul P; Maron M; Appelbaum E; Neisius U; Maron BJ; Burke MA; Chen B; Pagant S; Madsen CV; Danielsen R; Arngrimsson R; Feldt-Rasmussen U; Seidman JG; Seidman CE; Gunnarsson GT
    Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28798024
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
    Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
    Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey.
    Schaefer E; Mehta A; Gal A
    Acta Paediatr Suppl; 2005 Mar; 94(447):87-92; discussion 79. PubMed ID: 15895718
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea.
    Cho E; Park JT; Yoo TH; Kim SW; Park CW; Han SS; Kim YH; Kwon YJ
    Kidney Res Clin Pract; 2024 Jan; 43(1):71-81. PubMed ID: 38213034
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population.
    Terryn W; Poppe B; Wuyts B; Claes K; Maes B; Verbeelen D; Vanholder R; De Boeck K; Lameire N; De Paepe A; De Schoenmakere G
    Nephrol Dial Transplant; 2008 Jan; 23(1):294-300. PubMed ID: 17804462
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
    Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
    Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
    [TBL] [Abstract][Full Text] [Related]  

  • 77. First 2 Fabry Cases with Novel Mutation and Their Associated Clusters in Malaysia.
    Tang ASO; Wong QY; Pao Lin Ting I; Selvesten P; Yeo ST; Chew LP; Fam TL; Tan CHH
    Am J Case Rep; 2021 Aug; 22():e932923. PubMed ID: 34354036
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Screening for Fabry disease among male patients on hemodialysis in Awaji Island.
    Shimizu M; Fujii H; Kono K; Watanabe K; Goto S; Nozu K; Nakamura K; Nishi S
    Ther Apher Dial; 2022 Dec; 26(6):1187-1192. PubMed ID: 35261182
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Frequency of Fabry disease in a juvenile idiopathic arthritis cohort.
    Paim-Marques L; Cavalcante AV; Verçosa I; Carneiro P; Souto-Maior M; Marques E; Appenzeller S
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):91. PubMed ID: 34118938
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.